Enzymatica publ AB
The answer first
Does Enzymatica beat the market?
Yes, Enzymatica has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 48% of Nordic stocks
- Quality72
- Value5
- Trend77
No. 63 of 195 in healthcare
Max for seven days
Follow Enzymatica with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Enzymatica
Your first answer is free, no account needed.
Do you own Enzymatica, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Enzymatica and a few more. Free, no card.
Super Stock+44.6%In short
- Enzymatica has risen 27.0% over the past year, including dividends.
- Overall, Enzymatica ranks better than 48% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 85.4%. The price is 92.6% below its peak now.
What do analysts think of Enzymatica?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 48% of Nordic stocks.
No. 63 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 81 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.18
- Asset turnoverSales divided by everything the company owns0.42
- Return on equityProfit divided by equity−44.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 166 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity6.1
- P/SPrice divided by sales11.2
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 46 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+29.0%
- 6 months+0.8%
- 9 months+20.0%
- 12 months+27.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Enzymatica
One fund we follow owns Enzymatica. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Enzymatica
Enzymatica publ AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 17 employees.
Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.


See the full analysis of Enzymatica.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card